Healthcare / Medical DevicesNasdaqCM
$6.67
-0.14 (-2.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.5M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$242M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-64.1%
↓Gross Margin
70.8%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+34.1%
FCF CAGR
—
FCF margin
-238.8%
FCF / Net income
0.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.1M · net income $-42.6M · FCF $-38.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.1M | $16.1M | $10.7M | $7.2M | $6.7M |
| Net Income | $-42.6M | $-42.6M | $-27.8M | $-28.3M | $-28.7M |
| EBITDA | $-40.7M | $-40.7M | $-32.1M | $-27.7M | $-26.6M |
| EPS | — | — | -1.12 | -1.34 | -1.38 |
| Gross Margin | 70.8% | 70.8% | 65.9% | 59.9% | 45.2% |
| Operating Margin | -256.3% | -256.3% | -309.6% | -398.0% | -443.1% |
| Net Margin | -264.4% | -264.4% | -260.4% | -393.4% | -429.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.25 | 0.16 |
| Current Ratio | 6.55 | 6.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.4M | $-38.4M | $-23.5M | $-22.6M | $-25.8M |
| Returns | |||||
| ROE | -64.1% | -64.1% | -46.0% | -90.7% | -55.1% |
| Valuation | |||||
| P/B | 3.64 | 3.64 | 3.19 | 5.07 | 4.64 |
| Growth & Yield | |||||
| Revenue Growth | 50.7% | 50.7% | 48.4% | 7.8% | — |
| EPS Growth | — | — | 16.4% | 2.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.12 → n/d
Residual
+26.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.